TX-004HR Provides Robust Efficacy for Symptomatic Postmenopausal Vulvar and Vaginal Atrophy (VVA) while Providing Negligible to Very Low Systemic Absorption of Estradiol: Results of Clinical Phase 2 and 3 Trials Meeting Abstract

authors

publication date

  • December 1, 2016

webpage

published in

start page

  • 1374

end page

  • 1375

volume

  • 23

issue

  • 12